News from Zyme and the companies we work with.
Mogrify adds Dr. Lorenz Mayr to Board of Directors and Scientific Advisory Board
Cambridge, UK, 7th July 2020: Mogrify Ltd (Mogrify®), a UK biotechnology company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, today announced the appointment [...]
Dotmatics acquires BioBright to accelerate laboratory data automation for the Lab of the Future
Complementary expertise provides a single vendor solution to streamline data workflows from ‘instrument to insight’, boosting research efficiency End-to-end data automation will increase reproducibility of scientists’ experiments Unique blend of [...]
Avacta provides update on COVID-19 rapid antigen test development partnership with Cytiva
Positive initial data from first Affimer-based rapid test strips for SARS-COV-2 spike protein Cambridge and Wetherby, UK, 24 June 2020: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, [...]
TTP plc selected for technology advisory partnership with Cancer Research UK
Agreement to harness TTP’s industry expertise to assess the potential of emerging healthcare technologies and academic research Cambridge, UK, 22nd June 2020: TTP plc (TTP), a leading independent technology and product development [...]
Start Codon showcases the first cohort of companies from its life science business acceleration programme
Start Codon aims to rapidly translate the most disruptive and innovative life science research into successful companies and positive clinical outcomes The first cohort of four companies will debut at [...]
Dexamethasone identified by AI VIVO as high potential for treatment of COVID-19 ten weeks ago
Dexamethasone was shown to save the lives of seriously ill patients as a ground-breaking development in fight against COVID-19 Demonstrates the ability of AI VIVO’s unique phenotypic drug discovery methodology [...]
Avacta provides update on Affimer therapy for COVID-19 infection
Infectivity assays carried out in collaboration with Glasgow University show that Affimer reagents prevent infection of human cells by a SARS-COV-2 model virus Cambridge and Wetherby, UK, 18 June 2020: Avacta [...]
BIA Separations introduces PrimaS multi-mode ligand bioprocessing technology to facilitate development of advanced therapeutics
Novel platform initially focussed on high-resolution industrial scale processing of therapeutic mRNA Ajdovščina, Slovenia, 16 June 2020: BIA Separations, a leading bio-chromatography development and manufacturing company, today announced the introduction [...]
Dante Labs, Cambridge Cancer Genomics and Nonacus collaborate to provide precision oncology at scale
Partnership aims to deliver the most comprehensive, cost effective and high throughput cancer sequencing and interpretation service in Europe, to enable improved cancer patient management, treatment, and monitoring High throughput precision [...]
Avacta provides update on COVID-19 antigen diagnostic test development with Adeptrix
Highly specific prototype test detects the virus spike protein at clinically relevant concentrations Cambridge and Wetherby, UK, 09 June 2020: Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and [...]
CN Bio and Cambridge University identify novel regulatory pathway driving NASH
Paper published in Nature Metabolism demonstrates novel pathway regulating the underlying mechanism of liver fibrosis Research harnesses CN Bio’s liver-on-chip NASH disease model, to advance development of potential new medicines [...]
Base Genomics announces company launch and raises $11 million USD to commercialize epigenetic technology for early and sensitive detection of cancer from liquid biopsy
Epigenetics company Base Genomics launches, based on a new invention to sequence DNA methylation developed at the Ludwig Institute for Cancer Research Branch at the University of Oxford The technology, [...]
